|Articles|October 1, 2002

Cardiorenal Differences Among NSAIDs and Coxibs: Real-World Experience
Volume 8
Issue 15 Suppl

Cyclooxygenase-2-Specific Inhibitors and Cardiorenal Function: A Randomized, Controlled Trial of Celecoxib and Rofecoxib in Older Hypertensive Osteoarthritis Patients

Author(s)Andrew Whelton, John G. Fort, Joseph A. Puma

Download PDF: Cyclooxygenase-2-Specific Inhibitors and Cardiorenal Function: A Randomized, Controlled Trial of Celecoxib and Rofecoxib in Older Hypertensive Osteoarthritis Patients

Articles in this issue

over 23 years ago

Article

Participating Faculty

over 23 years ago

Article

Cardiorenal Differences Among NSAIDs and Coxibs: Real-World Experience

over 23 years ago

Article

Prevalence of Cardiovascular Disease Risk Factors Among US Adults With Self-Reported Osteoarthritis: Data from the Third National Health and Nutrition Examination Survey

over 23 years ago

Article

Comparison of the Baseline Cardiovascular Risk Profile Among Hypertensive Patients Prescribed COX-2-Specific Inhibitors or Nonspecific NSAIDs: Data From Real-Life Practice

over 23 years ago

Article

Blood Pressure Destabilization and Related Healthcare Utilization Among Hypertensive Patients Using Nonspecific NSAIDs and COX-2-Specific Inhibitors

over 23 years ago

Article

Cost of Heart Failure Among Hypertensive Users of Nonspecific NSAIDs and COX-2-Specific Inhibitors

over 23 years ago

Article

Differences Between COX-2-Specific Inhibitors: Clinical and Economic Implications

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!

Related Content

The Health Information Technology Special Issue: Tracking Expansion Across Settings, Technologies, and Stakeholders

ByNate C. Apathy, PhD

January 27th 2026

Building Trust: Public Priorities for Health Care AI Labeling

ByMorgan L. Sielaff, BS,Jodyn Platt, PhD, MPH,Sean Tan, MPP,Kerry A. Ryan, MA,Paige Nong, PhD,Sharon L. R. Kardia, PhD

January 27th 2026

Ambient AI Tool Adoption in US Hospitals and Associated Factors

ByFreddie Yang, MA,Ilana Graetz, PhD

January 27th 2026

Motivating and Enabling Factors Supporting Targeted Improvements to Hospital-SNF Transitions

ByTaylor I. Bucy, PhD,John P. McHugh, PhD,Dori A. Cross, PhD

January 26th 2026

Specialty and Operator Status Influence Electronic Health Record Use Variation

ByPhillip D. Jenkins, MD,Gary Grunkemeier, PhD,Elizabeth Weirich, DO,An Dinh, MS,Ruchi Thanawala, MD, MS,Jeffrey A. Gold, MD,Julie Doberne, MD, PhD

January 22nd 2026

Latest CME

Online Article

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy

AJMC Supplement

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

2.0 Credits / Pain Management

Cyclooxygenase-2-Specific Inhibitors and Cardiorenal Function: A Randomized, Controlled Trial of Celecoxib and Rofecoxib in Older Hypertensive Osteoarthritis Patients

Articles in this issue

Newsletter

Related Content

The Health Information Technology Special Issue: Tracking Expansion Across Settings, Technologies, and Stakeholders

Building Trust: Public Priorities for Health Care AI Labeling

Ambient AI Tool Adoption in US Hospitals and Associated Factors

Motivating and Enabling Factors Supporting Targeted Improvements to Hospital-SNF Transitions

Specialty and Operator Status Influence Electronic Health Record Use Variation

Latest CME

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

Trending on AJMC

Prior Authorization Ranked Top Barrier to Health Care Access After Cost

Contributor: The Majority (57.5%) of Commercially Insured Patients Had 1 or More Chronic Conditions in 2024

Vutrisiran Improves Survival, Cardiovascular Outcomes Across Age Groups in ATTR-CM

FDA Flags Administration Concerns for Aquestive's Noninvasive Epinephrine Film

Most Patients With MCL in Study of Pirtobrutinib Show Stable or Improved Physical Symptoms, QOL